



(51) International Patent Classification:

C07D 487/04 (2006.01) *C07D 491/147* (2006.01)
A61K 31/519 (2006.01) *C12Q 1/00* (2006.01)
A61K 49/00 (2006.01) *G01N 33/58* (2006.01)
A61K 51/04 (2006.01)

(21) International Application Number:

PCT/CA2012/000285

(22) International Filing Date:

3 April 2012 (03.04.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/471,322 4 April 2011 (04.04.2011) US

(71) Applicant (for all designated States except US):
PHARMASCIENCE INC. [CA/CA]; Suite 100, 6111
Royalmount Avenue, Montreal, Québec H4P 2T4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAURENT, Alain**
[CA/CA]; Suite 100, 6111 Royalmount Avenue, Montreal,
Québec H4P 2T4 (CA). **ROSE, Yannick** [CA/CA]; Suite
100, 6111 Royalmount Avenue, Montreal, Québec H4P
2T4 (CA). **MORRIS, Stephen** [CA/CA]; Suite 100, 6111
Royalmount Avenue, Montreal, Québec H4P 2T4 (CA).
JAQUITH, James [CA/CA]; Suite 100, 6111 Royalmount
Avenue, Montreal, Québec H4P 2T4 (CA).

(74) Agent: **SHEAHAN, Ryan**; Stikeman Elliott LLP, Suite
1600, 50 O'Connor Street, Ottawa, Ontario K1P 6L2 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PROTEIN KINASE INHIBITORS

(57) Abstract: The present invention relates to novel kinase inhibitors. Compounds of this class have been found to be effective in-
hibitors of protein kinases; including members of PDGFR and VEGFR families.



WO 2012/135937 A1